Table 3.

Unadjusted and Adjusted Hazard Ratios for Developing ESRD in Patients with moderate to severe TID vs. none or mild TID.

	Unadjusted		Adjusted^*
	HR (95% CI)	p-value	HR (95% CI)	p-value
Overall sample	5.2 (2.0, 13.4)	0.001	4.1 (1.4, 12.1)	0.01
In the subset of patients with GFR≥ 60 mL/min/1.73m²	6.4 (1.7, 23.7)	0.006	6.2^** (1.7, 23.2)	0.008
Excluding class I/II LN	4.7 (1.8, 12.3)	0.001	3.9 (1.3, 11.7)	0.02
In the subset of patients with proliferative LN	3.6 (1.3, 10.0)	0.01	4.6^***(1.4,14.8)	0.01
Excluding patients younger than 17 years old	5.0 (1.8, 14.4)	0.003	3.4 (1.1, 10.9)	0.04
Excluding 11 patients with < 1 year follow-up time	3.8 (1.2, 11.6)	0.02	4.0 (1.3, 12.5)	0.02
Adding TII into the models			3.8 (1.2, 11.5) (HR for TII 0.54 (0.15, 2.0), p=0.35)	0.002
Including 14 patients with LN on biopsy, but insufficient information to verify ACR/SLICC criteria	5.1 (2.0, 13.3)	0.001	4.3 (1.5, 12.9)	0.008

All models were adjusted for age, eGFR as a continuous variable, and LN class (proliferative vs. other), unless otherwise specified

^**

Adjusted for age only

^***

Adjusted for age and eGFR as a continuous variable